Navigation Links
GS1 Canada and GHX Align to Make Canada's Healthcare Supply Chain More Efficient and Effective
Date:6/23/2009

LOUISVILLE, Colo. and TORONTO, June 23 /PRNewswire/ -- GS1 Canada and GHX have agreed to form a strategic alliance to create a global standards-based product registry for healthcare products. The alliance is being established to dramatically improve the accuracy and clarity of electronic data transactions used in ordering, purchasing, shipping and receiving of healthcare and pharmaceutical products and, in turn, to achieve significant time and cost savings for Canada's healthcare system. GHX, through the utilization of the Health ConneXion(TM) data pool, a healthcare-focused data pool certified by GS1's Global Data Synchronization Network (GDSN), will assist GS1 Canada in its creation of the registry. The registry is designed to be the source of accurate product information for healthcare organizations across Canada.

GS1 Canada is the nation's leading not-for-profit organization in the development of global standards for electronic business and supply chain processes. As a business hub for healthcare, GHX enables healthcare providers and suppliers to reduce costs and improve margins by automating processes, reducing operating expenses and increasing knowledge-based decision making.

"Global standards are connecting the Canadian healthcare sector from end to end. This is enabling consistent product data to move between healthcare trading partners, suppliers and providers, improving supply chain efficiency and enabling traceability, which ultimately will improve patient safety and cost efficiency," stated N. Arthur Smith, president and chief executive officer, GS1 Canada. "This partnership with GHX, a trusted global supply chain partner, is part of GS1 Canada's ongoing commitment to support the Canadian healthcare sector in providing outstanding care, while ensuring a sustainable and cost-effective system."

GS1 Canada and GHX are seeking to mitigate current healthcare supply chain challenges by creatin
'/>"/>

SOURCE GHX; GS1 Canada
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. American Chemistry Council Responds to Health Canadas Proposed Phthalates Restrictions
2. Government of Canada supports research to help address medical isotope shortage
3. Havels Incorporated Expands Successful EchoStim(R) Ultrasound Needles into Canada
4. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
5. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
6. MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage
7. Thousands of Canadas best minds converge at Congress 2009
8. Government of Canada supports research to improve the health of future generations of Canadians
9. AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada
10. Palomar Medical to Market Quantels SINON Tattoo Removal Laser in the United States and Canada
11. Xoft Receives Health Canada Regulatory Approval for the Axxent(R) Electronic Brachytherapy System
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Binge Drinking Not Just a Rite of the Young 62247 1Binge Drinking Not Just a Rite of the Young 62247 2Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 1Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 1Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 3
Other Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8